GLP-1 Lifetime Cost — Ozempic / Wegovy / Mounjaro vs Lifestyle vs Bariatric

What This Calculator Does

The GLP-1 Lifetime Cost Calculator answers the only question the marketing pages won’t: once you start Ozempic, Wegovy, or Mounjaro, what’s the all-in financial commitment over the decade you’ll likely be on it?The math is dominated by a single uncomfortable finding — the STEP-4 trial showed roughly 70% regain within 12 months of discontinuation, which means the realistic baseline most users don’t price in is “take it forever.”

The calculator pulls four numbers most cost calculators ignore: the insurance multiplier (full prior-auth cuts cash price ~90%; no coverage stays at 100%), the comorbidity offset (T2D or established CV reduces 10-yr healthcare cost ~$30K per ADA + KFF analysis), the regain trajectory after discontinuation, and the bariatric-surgery counterfactual (~$27K one-time, ~30% regain over 10 yrs). The output is a net lifetime number that lets you compare GLP-1 against lifestyle programs and bariatric surgery on the same axis — which is the comparison that actually matters when you’re deciding.

The Math / Formula / How It Works

Two STEP trials (Wilding 2021, Rubino 2021) anchor the efficacy numbers. STEP-1 showed 14.9% mean weight loss at 68 weeks on semaglutide 2.4 mg. STEP-4 then withdrew half the responders and showed a mean ~7-point BMI rebound at 12 months off-drug — roughly 67-70% of lost weight regained. The SURMOUNT-1 trial for tirzepatide hit 22.5% mean loss, the highest in the class to date. The SELECT trial layered on the cardiovascular finding that locks in the comorbidity offset: 20% reduction in major adverse cardiovascular events in obese patients with established CV disease — the result that anchors the $30K KFF / ADA cost offset.

A worked example. A 45-year-old at 220 lb with no T2D, no insurance coverage, paying the GoodRx 2025 cash median ($1,200/mo for Wegovy), planning 18 months on drug: $1,200 × 1.0 × 18 = $21,600 drug cost. No comorbidity offset because there’s no T2D/CV indication. Expected loss bounded at 20% body weight = 44 lb. Post-drug regain at 70% of loss = ~31 lb back within 36 months. Net lifetime cost: $21,600. Now flip the comorbidity flag to T2D: net drops to −$8,400(the offset exceeds the drug cost). That sign change is why “is GLP-1 worth it” has different answers for different patients.

How to Use This Calculator

1. Enter your current weight and target weight. STEP trial efficacy caps the achievable loss at ~20% of starting weight; targets below that are realistic, above are aspirational.
2. Pick your insurance coverage tier. Full prior-auth-approved coverage drops effective monthly cost ~90%; partial / step-therapy ~55%; cash payers eat the full GoodRx price.
3. Enter the monthly cash price for your specific drug. GoodRx 2025 medians: Ozempic $1,030, Wegovy $1,360, Mounjaro $1,070, Zepbound vials $349-549 direct-from-Lilly.
4. Set expected duration on drug. Real-world adherence drops ~50% by year 2 due to cost, side effects, and supply. Maintenance therapy may be lifelong; budget honestly.
5. Set the regain rate post-discontinuation. STEP-4 default is 70%; lifestyle-disciplined patients sometimes hold 40-50%; non-adherent patients regain 80-90%+.
6. Mark T2D or established CV. This is the single biggest swing in the calculator — the comorbidity offset can flip the verdict from “long-term cost driver” to “cost-effective.”

Three Worked Examples

Example 1 — Off-label cash payer for cosmetic weight loss

A 38-year-old at 195 lb, no T2D/CV, no insurance coverage for weight loss, paying $1,200/mo cash for Wegovy, planning 12 months. Drug cost = $14,400. No comorbidity offset. Expected loss bounded at 20% × 195 = 39 lb to a target of 156. Post-discontinuation regain at 70% = 27 lb back within 3 years. Net lifetime cost: $14,400 for ~12 lb durable loss after regain. Effective cost per durable pound: ~$1,200/lb. Verdict tilts toward “long-term cost driver” — at this efficiency, lifestyle programs and bariatric surgery win on cost-per-durable-pound.

Example 2 — T2D patient with full insurance coverage

A 52-year-old with T2D at 250 lb, Ozempic 2 mg with full prior-auth coverage, $1,030 list × 0.10 multiplier = $103/mo effective copay. Planning 36 months (chronic management). Drug cost = $3,708. T2D comorbidity offset = $30,000 in 10-yr healthcare cost reduction (KFF / ADA). Net lifetime cost = −$26,292. The drug pays for itself ~8x over through complication prevention. Verdict: “Cost-effective with T2D/CV.” This is the population where the GLP-1 economics work cleanly.

Example 3 — Severe obesity, partial coverage, comparing bariatric

A 44-year-old with BMI 42 (no T2D yet), Wegovy with partial coverage requiring step therapy, $1,360 × 0.45 = $612/mo effective. Planning 60 months chronic therapy. Drug cost = $36,720. No T2D offset. Bariatric surgery alternative: $27,500 one-time, ~30% regain over 10 yrs (durable). Lifestyle alone: ~5% sustained loss per CDC, $12K over 5 yrs of programs. The calculator produces all three trajectories side-by-side: bariatric wins on cost and durability for severe obesity without comorbidities, but only if surgical risk is acceptable. GLP-1 wins on reversibility.

Common Mistakes

• Pricing GLP-1 as a 12-month diet drug.STEP-4 and SELECT both reframed it as chronic therapy, like a statin. If you stop, you regain. The honest budget horizon is 5-30 years, not 12 months. Most cost-shock comes from running the calculator with a 12-month duration when the realistic duration is “indefinite.”
• Trusting compounded GLP-1 quality + supply. Compounding pharmacies offered $200-400/mo semaglutide or tirzepatide during the 2022-2024 shortage, but the FDA crackdown in late 2024 plus normalizing brand-name supply means compounding is becoming illegal. Quality, sterility, and dose consistency vary widely. Brand-name with patient assistance (Lilly direct, Novo Nordisk savings card) is the safer long-term path.
• Assuming Medicare will cover for weight loss. As of 2025, Medicare Part D excludes weight-loss drugs by statute. Ozempic + Mounjaro are covered for T2D; Wegovy + Zepbound are NOT covered for weight loss. Bipartisan bills are pending, but plan as if coverage doesn’t come — and budget the cash price into your retirement spending model.
• Underestimating side-effect drop-off.Real-world adherence drops ~50% by year 2 — GI side effects (nausea, vomiting, gastroparesis), gallbladder issues, muscle loss, and cost fatigue all contribute. The calculator’s duration field should reflect realistic adherence, not best-case intent.
• Ignoring the comorbidity-offset gate.The $30K offset only applies if you have T2D or established CV. Off-label use for cosmetic weight loss has no comorbidity offset — and is also the use case where insurance won’t cover. Stack those two facts and the cost picture changes dramatically.
• Skipping the bariatric comparison.For BMI 35+ without comorbidities, bariatric surgery typically wins on cost-per-durable-pound and on durability of loss. GLP-1 wins on reversibility and lower upfront risk. The calculator’s three-line counterfactual is the picture worth showing your physician.

How to Read the Verdict

1. Net lifetime cost below $5K with T2D/CV → strongly cost-effective. The drug pays for itself through complication prevention. Continue indefinitely under specialist oversight; the SELECT-trial CV protection is a meaningful prevention bonus.
2. Net lifetime cost $5K-25K, severe obesity (BMI 35+) without T2D →case-by-case. Run the bariatric counterfactual; if you’re a surgical candidate and want durable loss, bariatric typically wins on cost-per-durable-pound. If you want reversibility or are surgery-averse, GLP-1 stays.
3. Net lifetime cost above $25K, off-label cosmetic use → long-term cost driver. Lifestyle programs ($150-300/mo) plus a structured TDEE plan and a strength-training routine produce comparable durable loss for <10% of the GLP-1 lifetime cost — at the cost of requiring sustained behavior change.

When GLP-1 Beats Lifestyle and Bariatric

Three conditions stack the GLP-1 case: (1) T2D or established CV (turns on the comorbidity offset), (2) insurance coverage (drops effective monthly cost 55-90%), and (3) willingness to view it as chronic therapy (avoids the regain trap). All three present: GLP-1 is usually the right answer. None present (off-label, cash-pay, planning 12-month course): GLP-1 is usually the wrong answer on economics — though may still be right for medical reasons your physician will weight differently. Pair this calc with the chronic illness lifetime cost calculator if you have T2D, to see the comorbidity-prevention math directly. For the underlying body composition picture, the calorie / TDEE calculator gives the daily-intake floor under any of these paths, and the biological age calculator shows the longevity dividend that body-composition normalization produces independent of the path you choose.